LEGN · earnings call history
Legend Biotech Q2 FY26 — Strong CARVYKTI Growth and In Vivo CAR-T Progress
Read the briefLegend Biotech Q1 FY26 — Strong CARVYKTI Sales and Pipeline Progress
Read the briefLegend Biotech Q4 FY25 — CARVYKTI Drives Profitability and Pipeline Expansion
Read the briefBrowse all US companies on the earnings-call register.